Viriom company at ChemRar High-Tech Center develops innovative antiviral drugs and combinations, methods of treatment and diagnosis.
In 2009 Viriom and Swiss company F. Hoffman-La Roche Ltd. signed a licensing agreement under which Viriom obtained the rights to develop new drugs against HIV/AIDS and the rights to their commercialization all over the world.
In 2013 Viriom expanded its antiviral portfolio with a program for the development of innovative drugs for the treatment of hepatitis B.
Viriom conducts research both in Russia, using the experience and knowledge of Russian scientists, and abroad in the framework of a broad international partnership. Viriom’s international partners include such companies and research organizations as Hoffmann-La Roche, Fox Chase Oncology Center, The Scripps Research Institute, Moscow Institute of Physics and Technology, Chumakov Institute of Poliomyelitis and Viral Encephalitides of the Russian Academy of Medical Sciences.